Mesa Labs director buys 900 shares at $113.69

Mesa Laboratories Inc. director R. Tony Tripeny reported an open-market purchase of 900 shares of the company’s common stock on 2026-08-13 at a price of $113.69 per share.

Rhea-AI Filing Summary

Mesa Laboratories Inc. director R. Tony Tripeny reported an open-market purchase of 900 shares of the company’s common stock on 2026-08-13 at a price of $113.69 per share. Following this transaction, Tripeny’s directly held stake increased to 6,298 shares of common stock.

Insider Trade Summary

Net Buyer: 900 shares

Net Buy 1 txn

Insider Tripeny R Tony

Role Director

Bought 900 shs ($102K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	900	$113.69	$102K

Holdings After Transaction: Common Stock — 6,298 shares (Direct)

Key Figures

Shares Purchased: 900 shares Purchase Price: $113.69 per share Shares Owned After: 6,298 shares +2 more

5 metrics

Shares Purchased 900 shares Common stock bought on 2026-08-13 in a non-derivative transaction

Purchase Price $113.69 per share Price for the 900 common shares acquired on 2026-08-13

Shares Owned After 6,298 shares Total directly held Mesa Laboratories common shares after the transaction

Net Buy Shares 900 shares Net buy direction across all reported transactions in this Form 4

Buy Transactions Count 1 Number of buy transactions reported for this date

Key Terms

Common Stock, non-derivative, Purchase in open market or private transaction

3 terms

Common Stock financial

"security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

non-derivative financial

"transaction_type: "non-derivative""

Purchase in open market or private transaction financial

"transaction_code_description: "Purchase in open market or private transaction""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did MLAB director R. Tony Tripeny report on this Form 4?

R. Tony Tripeny reported a purchase of 900 shares of Mesa Laboratories common stock on 2026-08-13. The transaction was reported as a non-derivative, open-market or private purchase at a price of $113.69 per share, increasing his direct holdings.

At what price did R. Tony Tripeny buy MLAB (Mesa Laboratories) shares?

He bought the shares at $113.69 per share. The Form 4 classifies the trade as a non-derivative, open-market or private purchase of common stock, indicating a straightforward share acquisition rather than an option exercise or other derivative transaction.

How many Mesa Laboratories (MLAB) shares does R. Tony Tripeny own after this transaction?

After the reported purchase, Tripeny directly owns 6,298 shares of Mesa Laboratories common stock. This figure, disclosed as “shares following transaction,” reflects his direct beneficial ownership position after acquiring the additional 900 shares on 2026-08-13.

Was the recent MLAB insider purchase by R. Tony Tripeny made under a Rule 10b5-1 plan?

The transaction was not indicated as under a Rule 10b5-1 plan. The Form 4’s plan-status indicator is set to false, meaning the filer did not check the box affirming that the reported trade was executed pursuant to a pre-arranged trading plan.

What type of security did R. Tony Tripeny acquire in the latest MLAB Form 4 filing?

He acquired common stock of Mesa Laboratories in a non-derivative transaction. The Form 4 specifically lists the security title as common stock and categorizes the transaction type as non-derivative, confirming it was a direct share purchase rather than a derivative security exercise.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/17/2026 - 11:27 AM Accepted by SEC EDGAR 08/17/2026 - 11:27 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tripeny R Tony

(Last) (First) (Middle)

12100 W 6TH AVE

(Street)

LAKEWOOD COLORADO 80228

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MESA LABORATORIES INC /CO/ [ MLAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/13/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/13/2026		P		900	A	$113.69	6,298	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	John Sakys under Power of Attorney by Tony Tripeny	08/17/2006
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)